User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

12482

Interactions with Platform & by Email *

INTERACTIONS

1498

Unique # Participated *

PARTICIPANTS

374

Responses Validated *

VALIDATIONS

40

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definition and Scope of Study.....I-3
  
   Pharma Industry Hit by Economic Downturn.....II-1
Table 1: Worldwide Prescription Drugs Sales: 2006-2015 (includes corresponding Graph/Chart).....II-1
The Regional Impact.....II-1
1$300
   Emerging Markets to Drive Growth.....II-2
Biotechnology.....II-2
1$100
   Biotech Bankruptcies Rife in the Current Economic Downturn.....II-3
Economic Downturn Takes Toll on R&D.....II-3
1$100
   Outsourcing – A Mixed Bag.....II-42$200
   Generics – The Bright Spot.....II-6
Table 2: Increasing Share of Generics in the Global Pharmaceutical Market: 1995-2005 (In %) (includes corresponding Graph/Chart).....II-6
1$300
   Table 3: Generics Share in Select Markets Worldwide – United States, Germany, UK, Spain, Japan, Italy, France, Finland, Denmark, The Netherlands, Norway, and Ireland (includes corresponding Graph/Chart).....II-71$300
   Patent Expiries of Major Drugs: 2009-2012.....II-8
Patient Spending.....II-8
1$100
   Operational Restructuring.....II-9
Rising R&D Costs Call for Improved Efficiency.....II-9
Concerns Over Drug Safety and Side Effects Impede Sales.....II-9
1$100
   Policy Issues Threaten Innovation.....II-10
Regulatory Glitches and High Costs Hinder Biogeneric Growth.....II-10
1$100
   Opportunities Outside Drug Development.....II-11
Going Forward in Forward Integration.....II-11
Forward Integration into Diagnostics.....II-11
Opportunities in Healthcare.....II-11
1$100
   Down the Distribution Chain.....II-12
1$100
   Pfizer Reigns Supreme .....II-13
Table 4: Leading Global Pharmaceutical Companies Worldwide by Sales (2008, 2007, and 2006) - Pfizer, GlaxoSmithKline, Novartis, Sanofi-Aventis, AstraZeneca, Roche, Johnson & Johnson, Merck & Co., Abbott and Eli Lilly - in US$ Billion (includes corresponding Graph/Chart).....II-13
1$300
   Leading Prescription Drugs Worldwide – Lipitor Leads the Way.....II-14
Table 5: Leading Prescription Drugs Worldwide by Sales (2008, 2007, and 2006)- Lipitor, Plavix, Nexium, Seretide, Enbrel, Seroquel, Zyprexa, Remicade, Singulair and Levonox in US$ Billion (includes corresponding Graph/Chart).....II-14
Oncology Tops Therapeutic Classes.....II-14
1$300
   Table 6: Leading Therapeutic Classes Worldwide by Sales (2008, 2007, and 2006)- Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others in US$ Billion (includes corresponding Graph/Chart).....II-15
1$300
   Cholesterol Reducers.....II-16
Statins Lead the Way.....II-16
Emerging Leaders.....II-16
Table 7: Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes corresponding Graph/Chart).....II-16
1$300
   Lack of Product Differentiation Mars Prospects.....II-17
Zocor – The First Statin to Switch to OTC.....II-17
Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond.....II-17
Oncologics.....II-17
Oncologics/ Cancer Drugs – Largest Therapeutic Class.....II-17
High Unmet Needs to Drive Growth.....II-17
1$100
   Biologics to Reign Supreme.....II-18
Leading Drugs.....II-18
Leading Players.....II-18
Novel Therapies.....II-18
1$100
   Respiratory Drugs.....II-19
Leading Brands and Players.....II-19
Table 8: Leading Asthma Drugs Worldwide – Value Sales for the Years 2004-2008 for Seretide, Singulair, Symbicort and Pulmicort (in US$ Billion) (includes corresponding Graph/Chart).....II-19
1$300
   Table 9: Select COPD and Allergic Rhinitis Drugs Worldwide: Value Sales for the Years 2006-2008 for Spiriva, Nasonex and Zyrtec (In US$ Billion) (includes corresponding Graph/Chart).....II-20
Patent Expiries of Leading Respiratory Drugs: 2008 and Beyond.....II-20
Antipsychotics.....II-20
1$300
   Leading Schizophrenia Drugs.....II-21
Side Effects of Antipsychotics – A Major Issue.....II-21
Patent Expiries.....II-21
1$100
   Patent Expiries of Leading Anti-Psychotic Drugs.....II-22
Zyprexa Continues to Lose Market Share.....II-22
Risperdal Sales to Plunge, Following its Patent Expiry.....II-22
Generics - Yet to Make a Mark in Antipsychotics.....II-22
Increasing Use of Antipsychotics in Children Raises Concerns.....II-22
1$100
   Proton Pump Inhibitors.....II-231$100
   Patent Expiries of Leading Proton Pump Inhibitors: 2008 and Beyond.....II-24
Table 10: Leading Proton Pump Inhibitors Worldwide – Value Sales for the Years 2004 through 2006 (US$ Billion) - Nexium, Prevacid/Takepron, Protronix/Pantazol and AcipHex/Pariet (includes corresponding Graph/Chart).....II-24
Antidepressants.....II-24
1$300
   Patent Expiries of Leading Antidepressant Drugs Worldwide: 2005-2015.....II-25
Erythropoietins.....II-25
1$100
   Competitive Landscape in the Global Erythropoietin Market.....II-26
Leading Erythropoietin Drugs.....II-26
Table 11: Leading Erythropoietin Drugs Worldwide – Annual Revenues for the Years 2004 through 2007 in US$ Billion for Aranesp, Procrit/Eprex, Epogen and NeoRecormon (includes corresponding Graph/Chart).....II-26
1$300
   New and Pipeline Products.....II-27
Biogenerics Pose Imminent Threat.....II-27
Anti-Arthritics.....II-27
1$100
   Table 12: Leading Anti-arthritic Drugs Worldwide – Value Sales for Years 2006 through 2008 in US$ Billion - Enbrel, Remicade, Rituxan and Humira (includes corresponding Graph/Chart).....II-28
Anti-Epileptics.....II-28
1$300
   Disease Statistics.....II-29
Available Drugs.....II-29
Generics to Take the Lead in Anti-Epileptic Market.....II-29
1$100
   Table 13: Leading Anti-Epileptic Drugs Worldwide: Value Sales for years 2005 through 2007 in US$ Billion for Topamax, Lamictal, Depakote and Keppra (includes corresponding Graph/Chart).....II-30
Patent Expiries of Leading Anti-Epileptic Drugs.....II-30
New Launches.....II-30
Pipeline Drugs Bode Brighter Prospects.....II-30
1$300
   Pipeline Drugs in Antiepileptics.....II-31
Calcium Channel Blockers.....II-31
Antidiabetics.....II-31
1$100
   Table 14: Leading Anti-diabetic Drug Sales Worldwide: Value Sales for Years 2005 through 2008 in US$ Billion for Actos, Lantus, Avandia Franchise, Januivia and Byetta (includes corresponding Graph/Chart).....II-32
1$300
   Pharma M&A Activity in 2008.....II-331$100
   Aggressive M&A Deals by Japanese Companies.....II-34
Patent Expiries.....II-34
1$100
   Patent Expiries for 2008 and 2007.....II-35
New Product Approvals.....II-35
1$300
   Table 15: New Drugs Approval from 2003-2008 (includes corresponding Graph/Chart).....II-36

Table 16: Biologics Approvals from 2003-2008 (includes corresponding Graph/Chart).....II-36
1$300
   Table 17: Development of New Molecular Entities (Biological and Chemical) by Various Region/Country: Percentage Share Breakdown for the Periods 1998-2002 & 2003-2007 (includes corresponding Graph/Chart).....II-37

Table 18: Number of Compounds Under Development by Country/Region: Percentage Breakdown for the year 2007 (includes corresponding Graph/Chart).....II-37
1$300
   New Molecular Entities (NMEs) Approved by FDA in 2008.....II-38
New Biological Entities Approved by FDA in 2008.....II-38
1$100
   Research and Development.....II-39
Table 19: R&D Investments by Pharmaceutical Sector in US and Europe: 2005-2007 (includes corresponding Graph/Chart).....II-39
Cost Pressures.....II-39
R&D Productivity Slides Despite Increasing Investments.....II-39
1$300
   Aging Population Drives Demand.....II-40
Table 20: World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart).....II-40
1$300
   Biologics.....II-411$100
   Evolution Of The Global Pharmaceutical Industry.....II-421$100
   Drug Development Process – FDA Perspective.....II-43
Stages of Drug Development Process.....II-43
Drug Discovery.....II-43
Pre-Clinical Testing.....II-43
Clinical Trials.....II-43
1$100
   Phase I Clinical Trial.....II-44
Phase II Clinical Trial.....II-44
Phase III Clinical Trial.....II-44
New Drug Application.....II-44
FDA Review.....II-44
Phase IV Clinical Trials.....II-44
FDA’s Drug Safety Review – The Global Standard.....II-44
2$200
   Anti-arthritics.....II-46
COX-2 Inhibitors.....II-46
Antipsychotic Drugs.....II-46
1$100
   Anti-Ulcerants.....II-47
Codeine & Combinations.....II-47
1$100
   Combination Drugs.....II-48
Anti-Depressants.....II-48
Selective Serotonin Reuptake Inhibitors (SSRIs).....II-48
1$100
   Serotonin Noradrenaline Re-Uptake Inhibitors (SNRIs).....II-49
Serotonin Modulators (5-HT2 blockers).....II-49
Dopamine-norepinephrine Reuptake Inhibitors.....II-49
1$100
   Monoamine Oxidase Inhibitors (MAOIs).....II-50
Erythropoietin.....II-50
Proton Pump Inhibitors.....II-50
1$100
   Seizure Disorder Drugs.....II-511$100
   Antihistamines.....II-521$100
   Calcium Channel Blockers.....II-531$100
   Cholesterol Reducers.....II-54
1$100
   Table 21: Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Sanofi-Aventis, Novartis, Eli Lilly, Schering-Plough, Johnson & Johnson, and Bristol Myers Squibb (includes corresponding Graph/Chart).....II-551$300
   Table 22: Promotional Spending through Professional Detailing by Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, AstraZeneca, Novartis, Sanofi-Aventis, Eli Lilly, Johnson & Johnson, Schering-Plough and Wyeth (includes corresponding Graph/Chart).....II-56

Table 23: Direct-To-Consumer Promotional Spending By Major Pharma Companies (2006 and 2007) in US$ Million – Pfizer, GlaxoSmithKline, Merck, Bristol Myers Squibb, Sepracor, AstraZeneca, Schering-Plough, Sanofi-Aventis, Boehringer Ingelheim and Eli Lilly (includes corresponding Graph/Chart).....II-56
1$300
   Table 24: E-Promotional Spending by Major Pharma Companies (2006 and 2007) in US$ Million – Merck, GlaxoSmithKline, Johnson & Johnson, Pfizer, Shire, Eli Lilly, Schering-Plough, AstraZeneca and Sanofi- Aventis (includes corresponding Graph/Chart).....II-57
1$300
   Merck & Co. and Schering-Plough to Merge.....II-58
Pfizer to Acquire Wyeth.....II-58
CSL and Talecris Biotherapeutics to Withdraw Merger Agreement.....II-58
AstraZeneca Partners with Merck to Analyze a New Combination of Anticancer
  Regimen.....II-58
1$100
   Sun Pharmaceutical Acquires Chattem.....II-59
Novartis Acquires 25% Stake in Alcon.....II-59
Takeda Acquires Millenium Pharmaceuticals.....II-59
1$100
   Teva Acquires Barr.....II-60
Invitrogen and Applied Biosystems Merge.....II-60
Eli Lilly Takes Over ImClone Systems.....II-60
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy.....II-60
1$100
   Fresenius Acquires APP Pharmaceuticals.....II-61
TPG Acquires 50% Stake in SIA International.....II-61
GSK Acquires Sirtris.....II-61
Shire Aquires Controlling Interest in Jerini.....II-61
Boehringer Ingelheim to Purchase Actimis Pharmaceuticals.....II-61
1$100
   Sanofi Pasteur Acquires Acambis.....II-62
Sanofi-Aventis Acquires Symbion.....II-62
Nordic and Avista Acquires ConvaTec.....II-62
King Pharmaceuticals Acquires Alpharma.....II-62
1$100
   Shionogi Acquires Sciele.....II-63
Ranbaxy Inks Indian Marketing License for GLIADEL® with BioPro.....II-63
Tibotec Gains EC Approval for PREZISTA®’s Extended Indication.....II-63
1$100
   GSK and Neptunus to Set up Joint Venture for Developing Flu Vaccines.....II-64
AstraZeneca Obtains TRO for Generic Pulmicort Respules.....II-64
Solvay Pharmaceuticals Enters Into a License Deal with Depomed.....II-64
1$100
   AstraZeneca Enters into an Agreement with Par Pharmaceutical.....II-65
BioReliance and Provecs Enter into Agreement.....II-65
Cornerstone BioPharma and Critical Therapeutics Merge to Form Cornerstone
  Therapeutics.....II-65
1$100
   GSK to Acquire Genelabs.....II-66
Lpath and Merck Serono Forge Partnership.....II-66
Allergan and Spectrum Ink Collaboration Deal for Bladder Cancer Drug.....II-66
1$100
   EMD Signs Licensing and Collaboration Deal with Theratechnologies.....II-67
Medimetriks Receives License for Prescription Brands from Perrigo.....II-67
1$100
   Forest Partners with Phenomix for Developing Diabetic Drug.....II-68
GSK Biologicals and AFFiRiS Sign Collaboration Agreement.....II-68
Sanofi-Aventis Strengthens R&D Operations in the Chinese Market.....II-68
1$100
   UCB and Pfizer Establish Cyclofluidic.....II-69
Valeant Pharmaceuticals Completes Coria Laboratories Acquisition.....II-69
1$100
   MedImmune Inks Agreement with Omninvest over Reverse Genetic Technology.....II-70
Avidas Secures North American Rights of Crown’s Dermatology Products.....II-70
1$100
   Lilly Acquires Two Compounds for Early-Stage Tuberculosis Drug Pipeline.....II-71
Eli Lilly and Deciphera Enter into Collaboration and Licensing Deal.....II-71
1$100
   Roche, GlycArt and Genentech Sign Collaboration Agreement.....II-72
Cardinal Health Plans to Spin-Off Medical and Clinical Products Businesses.....II-72
Sanofi Pasteur Holding Acquires Acambis.....II-72
1$100
   Eisai Plans NDA Submission for Insomnia Drug.....II-73
GlaxoSmithKline Enter into Strategic Alliance with Cellzome.....II-73
1$100
   Ablynx and Merck Serono Sign Nanobodies® Agreement.....II-74
GlaxoSmithKline and Valeant Enter into Collaborative Agreement.....II-74
1$100
   Noven Enters Supply and License Agreements with P&G Pharmaceuticals.....II-75
Eli Lilly Acquires SGX Pharmaceuticals.....II-75
SymBio Pharmaceuticals Enters into a License Agreement with Eisai.....II-75
1$100
   Roche Sells Four Pharmaceutical Products to Meda AB.....II-76
AstraZeneca Joins Hands with Abbott for Co-Promotion of Crestor.....II-76
1$100
   Gilead Sciences Inks Atripla®, HIV Drug Distribution Deal with Merck.....II-77
Eisai China Enters into Licensing Deal with Health Vision.....II-77
1$100
   GSK and Harvard Stem Cell Institute Team Up for Drug Discovery.....II-78
Teva Acquires Bentley Pharmaceuticals.....II-78
Roche to Acquire ARIUS Research.....II-78
1$100
   GlaxoSmithKline and Actelion Collaborate.....II-79
GSK Enters into Product Disinvestment Agreement with Aspen.....II-79
1$100
   Lupin Forges Marketing Alliance with ASCEND for Suprax® Tablets.....II-80
Merck Serono Inks Multiple Sclerosis Drug-Development Deal with Bionomics.....II-80
1$100
   European Commission Approves Kuvan® of Merck Serono.....II-81
GSK Collaborates with Mpex for Developing Anti-Bacterial Drugs.....II-81
Eli Lilly Announces Development & Licensing Agreement with TransPharma.....II-81
1$100
   Mylan Obtains Exclusive Marketing Rights for Glatiramer from NATCO.....II-82
Sepracor Acquires Oryx Pharmaceuticals.....II-82
1$100
   Mylan Takes Over Merck’s Outstanding Generics Operations.....II-83
Gilead Acquires Cicletanine Business from Navitas.....II-83
1$100
   King Pharmaceuticals to License Third Opioid Analgesic Product.....II-84
BioPhausia Acquires Prescription Pharmaceutical Offerings from AstraZeneca.....II-84
Ranbaxy Enters into Strategic Product Development Agreement with Merck.....II-84
1$100
   EUSA Pharma Acquires Cytogen Corporation.....II-85
Dr. Reddy’s Announces Two Major Acquisitions.....II-85
EUSA Divests Stake in Antibody Research and Oncology Product to IDD.....II-85
1$100
   Sanofi Pasteur Delivers H5N1 Bulk Vaccine Antigen to HHS.....II-86
Ranbaxy Inks Strategic Business Alliance with Orchid.....II-86
1$100
   Pfizer Settles Patent Litigation for Lipitor with Ranbaxy.....II-87
GSK Enters into Collaboration with Regulus Therapeutics.....II-87
1$100
   Janssen to Launch J&J Group’s New Drugs in Japan.....II-88
Roche Alliance Partner Obtains Approval for Actemra in Japan.....II-88
Abbott Receives Japanese Approval for Rheumatoid Arthritis Drug, HUMIRA®.....II-88
1$100
   Dr. Reddy’s Completes Acquisition of Jet Generici Srl.....II-89
Eli Lilly, Transition Therapeutics Announce Licensing and Partnership
  Agreement.....II-89
Dr. Reddy’s and 7TM Sign Drug Discovery Agreement for Selected Drug Targets.....II-89
1$100
   Endo Pharmaceuticals Obtains US Rights for Novartis’ Voltaren® Gel.....II-90
Pfizer to Take Over Serenex.....II-90
1$100
   Sanofi-aventis, Amyris, iOWH Sign Semisynthetic Artemisinin Development Deal.....II-91
AstraZeneca Files sNDA for Depressive Disorder Drug, Seroquel XR™.....II-91
1$100
   Forest, Mylan Amend Bystolic Agreement.....II-92
Fujifilm to Acquire Stake in Toyama Chemicals.....II-92
Graceway Takes Over Estrasorb.....II-92
1$100
   Ranbaxy Announces De-Merger of New-Drug Discovery Research Unit.....II-93
AstraZeneca Inks Deal with Nomura Phase4 Ventures to Form Albireo.....II-93
Cellegy to Merge with Adamis Pharmaceuticals.....II-93
Mylan Reaches Accord with Novartis for Femara®’s Generic Product.....II-93
1$100
   Dyax Signs Licensing and Development Agreements with Sanofi-aventis.....II-94
AstraZeneca Files for EU Approval of Seroquel XR™.....II-94
MedImmune Files Biologics License Application for motavizumab to FDA.....II-94
Farmavita, Belupo Sign Contract for Strategic Merger.....II-94
1$100
   Pfizer Japan Secures Production and Marketing Approval for Champix®.....II-95
Eisai Enters into License Agreement with Abbott.....II-95
1$100
   Eisai Takes Over MGI Pharma.....II-96
KV Pharmaceutical to Acquire Rights for Gestiva™ from Hologic.....II-96
Forest and Novexel Enter into Licensing Agreement.....II-96
1$100
   Dr. Reddy’s Enters Settlement Agreement with Novartis for Exelon®.....II-97
Taisho and Pfizer Sign Agreement for TS-032.....II-97
Crucell Enters into Agreement with Sanofi Pasteur.....II-97
1$100
   EMEA Approves Second Biogeneric EPO, Retacrit.....II-98
Endo Pharmaceuticals Licenses AZ-003 from Alexza.....II-98
Schering-Plough and Centocor Modify Existing Distribution Agreement.....II-98
1$100
   GSK and Santaris Pharma Collaborate in RNA Antagonists Research.....II-99
GSK Acquires Reliant Pharmaceuticals.....II-99
1$100
   Eisai and Minophagen Ink In-Licensing Agreement for Liver Disease/ Allergic Disease
  Agents.....II-100
Bristol-Myers, Gilead Extend Agreement to Commercialize ATRIPLA® in Europe.....II-100
1$100
   GSK and OncoMed Team Up for Antibody Therapeutics for Cancer Stem Cell
  Research.....II-101
GSK Allies with Galapagos for Antiviral and Antibacterial Development.....II-101
1$100
   Eisai and BioArctic Ink Licensing Deal for BAN2401.....II-102
Biogen and Neurimmune Join Hands to Develop Drugs for Alzheimer's Disease.....II-102
1$100
   Sanofi-aventis Institutes GDC, Pharmaceutical Development Center in India.....II-103
AstraZeneca Obtains Pediatric Exclusivity for ARIMIDEX® from FDA.....II-103
Covance to Build High-Tech Drug Development Facility.....II-103
1$100
   Schering-Plough Takes Over Organon BioSciences.....II-104
Takeda Launches Takeda San Francisco for Therapeutic Antibody Research.....II-104
GSK to Disinvest Lotronex®.....II-104
1$100
   Gilead and LGLS Enter Global License Deal for Fibrotic Diseases Therapy.....II-105
Watson Acquires Andrx.....II-105
1$100
   EPFL and Merck Serono Enter into Agreement.....II-106
Acura and King R&D Sign Licensing Agreement for Opioid Analgesic Products.....II-106
1$100
   Eli Lilly Inks License Agreement with Glenmark Pharmaceuticals.....II-107
Wockhardt Takes Over Morton Grove Pharmaceuticals.....II-107
1$100
   GSK Enters into Collaboration with Tolerx for Development of Novel Therapies.....II-108
Chugai Pharmaceuticals Obtains Approval for Tarceva in Japan.....II-108
Eli Lilly Announces Strategic Alliance with MacroGenics.....II-108
1$100
   BMS, ImClone, Merck Serono Sign Erbitux® Agreement.....II-1091$100
   Wockhardt to Market Gnosis’ SAMe in India.....II-110
Alpharma Grants US License for Ketoprofen in Transfersome® Gel to IDEA.....II-110
Forest and Daiichi Sankyo Sign Contract to Co-Promote AZOR™.....II-110
Synta and GSK Sign Oncology Molecule Development Collaboration.....II-110
1$100
   Cyclacel to Take Over ALIGN Pharmaceuticals and ALIGN Holdings.....II-111
GSK Inks Antiviral and Antibacterial Drug Development Deal with Anacor.....II-111
1$100
   AMRI Enters into Research Collaboration with Cystic Fibrosis Foundation.....II-112
Mylan Takes over Merck Generics.....II-112
Kissei and Eisai Ink Licensing Deal for Glufast® Tablets.....II-112
1$100
   AMRI Inaugurates New Research Unit in Hyderabad.....II-113
Eisai Inks Co-Promotion Deal with Salix for COLAZAL® Capsules.....II-113
Kowa and Teva to Establish Joint Venture Generic Drug Firm in Japan.....II-113
1$100
   Nisshin Seifun Pulls Out of Joint Venture Nisshin Kyorin Pharmaceutical.....II-114
Chugai and Teijin Sign Agreement for Co-Development of Anti-Diabetic Drug.....II-114
MedImmune Inks Licensing Agreement with Novartis over Reverse Genetic
  Technology.....II-114
1$100
   EUSA Acquires Assets of Innocoll.....II-115
Noven Enters Supply and License Agreements with P&G Pharmaceuticals.....II-115
1$100
   Parion and Gilead Ink Deal to Develop Drug Candidates for Pulmonary Disease.....II-116
Noven Pharmaceuticals Acquires JDS Pharmaceuticals.....II-116
1$100
   HHS Places an Order with GSK for Bulk H5N1 Antigen.....II-117
Synthon Completes Laboratorios Rider Acquisition.....II-117
1$100
   Targacept Forges Partnership with GSK.....II-118
Dong Wha Signs Alliance with P&G Pharma to Develop Treatment Molecules for
  Osteoporosis.....II-118
Barr and Gedeon Richter Sign Pact over Generic Version of LAMISIL®.....II-118
1$100
   Santarus and Victory Pharma Enter Into Co-Promotion Agreement.....II-119
AMRI Enters into Collaboration for Research with Achaogen.....II-119
1$100
   SCI Collaborates with High Q Foundation for Research on Huntington’s Disease.....II-120
MonoSol Rx Signs License Agreement with Strativa Pharmaceuticals.....II-120
Eli Lilly to Launch Public-Private Partnership for Drug Research in
  Tuberculosis.....II-120
1$100
   Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal.....II-121
Strides Arcolab to Take Over Bio-Fermentation Facility in Italy.....II-121
Amgen to Take Over Alantos Pharmaceuticals.....II-121
1$100
   GlaxoSmithKline Establishes R&D Center in China.....II-122
Wockhardt Acquires Negma Laboratories.....II-122
Eisai Inks Exclusive Agreement with Solstice over NeuroBloc®.....II-122
1$100
   Ranbaxy to Acquire Be-Tabs Pharmaceuticals.....II-123
Pfizer Obtains Health Canada Approval for LIPITOR in Reducing Myocardial
  Infarction.....II-123
1$100
   GSK Allies with Wellcome to Develop Antibacterials for Hospital-Contracted
  Infections.....II-124
Bristol-Myers and Pfizer Ink Development and Commercialization Agreements.....II-124
1$100
   Cytos Biotechnology Grants Novartis with Global License for NicQb.....II-125
Swiss Federal Register Adds ACOMPLIA® to Reimbursement List.....II-125
1$100
   Wockhardt to Introduce Syrio Pharma’s B-Lift Product Range in India.....II-126
Eisai Acquires Morphotex.....II-126
Ranbaxy Obtains Approval for RAN™ Cefprozil Formulations in Canada.....II-126
1$100
   Roche Partners with Transgene to Focus on Therapeutic Vaccine Program.....II-127
Cardinal Health Divests Pharmaceutical Technologies and Services Segment to Blackstone
  Group.....II-127
1$100
   Roche to Acquire BioVeris Corporation.....II-128
Eli Lilly Acquires Hypnion.....II-128
Roche Takes Over THP, Broadens Antibody Research Facility.....II-128
1$100
   Oxford BioMedica Enters into Development Deal with Sanofi-Aventis for
  TroVax®.....II-129
Iroko Pharmaceuticals Acquires Rights to Indocin® and Aldomet® Products.....II-129
Asahi Kasei Inks Licensing Agreement with Eisai Korea over Vasodilator Eril®.....II-129
1$100
   Merck Obtains EU Approval for JANUVIA™ Type 2 Diabetes Drug.....II-130
Wockhardt Obtains FDA Approval for a Painkiller in the US.....II-130
1$100
   Ortho-McNeil Obtains Pediatric Extension for LEVAQUIN®.....II-131
GlaxoSmithKline Obtains FDA Approval for Tykerb®.....II-131
Terapia Ranbaxy Secures Marketing Approvals for 20 New Products.....II-131
Shionogi to Develop and Market BioCryst's peramivir in Japan.....II-131
1$100
   Abbott and Eisai Amend Co-Promotion Agreement over HUMIRA® in Korea and
  Taiwan.....II-132
Salix Acquires US Rights to Merck’s Two Oral Suspension Products.....II-132
1$100
   Takeda Expands Collaboration with XOMA in Potential Therapeutic Antibody
  Programs.....II-133
GSK Commences Phase III Clinical Trials of Tykerb®, a Post-Operative
  Lapatinib.....II-133
1$100
   Roche Grants Glaxo with Exclusive Licensing Rights to its ‘Orlistat’ Drug.....II-134
GSK and HGS Commence Phase III Trials of LymphoStat-B® in SLE.....II-134
GSK and Fabre-Kramer Ink Global Deal for Gepirone ER.....II-134
1$100
   Ranbaxy Signs Agreement with Zenotech for Biosimilars’ Global Launch.....II-135
Ranbaxy Inks Long-Term R&D Deal with GSK.....II-135
1$100
   Amgen Inks Three-year Aranesp Supply Agreement with Fresenius.....II-136
AstraZeneca to Take Over Arrow Therapeutics.....II-136
Eli Lilly Acquires ICOS Corporation.....II-136
Pfizer Plans to Takeover BioRexis.....II-136
1$100
   Solvay Inks Licensing Deal with Jazz Pharmaceuticals for LUVOX®.....II-137
Eisai’s ‘Pariet®, 10mg Tablets’ Receive Clearance for New Indication in
  Japan.....II-137
Eisai Receives EC Approval for Inovelon®.....II-137
Pfizer Receives Marketing Authorization for Sutent® in European Union.....II-137
1$100
   GlaxoSmithKline Obtains Approval to Market Wellbutrin XR® in the Netherlands.....II-138
Forest Laboratories Acquires US Biopharmaceutical Company, Cerexa.....II-138
1$100
   Mylan Laboratories Acquires 51.5% in Matrix.....II-139
DUSA Enters into an Agreement with Daewoong Pharmaceutical.....II-139
Penwest and Endo Amend Existing Contract on Opana® ER Collaboration.....II-139
1$100
   Eli Lilly Licenses Glucokinase Activator Program from OSI Pharmaceuticals.....II-140
Graceway Pharmaceuticals Acquires 3M Pharmaceuticals Business.....II-140
Ranbaxy Obtains FDA Approval for Atenolol Tablets.....II-140
1$100
   Gilead Sciences Acquires Myogen.....II-141
Gilead Sciences Acquires Raylo Chemicals.....II-141
1$100
   FDA Approvals for 2009, 2008 AND 2007.....II-142
2$200
   Amgen Receives Approval for Nplate(R) .....II-144
Takeda Wins FDA Marketing Approval for ULORIC .....II-144
Novartis and MMV Launch Coartem® Dispersible.....II-144
Ipsen and Medicis Receives FDA Approval for Dysport .....II-144
1$100
   Centocor Receives FDA Approval for Simponi .....II-145
Wyeth Receives FDA Approval for PRISTIQ™ .....II-145
GSK Receives FDA Approval for Promacta® .....II-145
Cephalon Receives FDA Approval for TREANDA .....II-145
Adolor Receives FDA Approval For Entereg(R) .....II-145
1$100
   Lundbeck Introduces Xenazine* (Tetrabenazine) Tablets.....II-146
Eisai US Receives FDA Approval for Banzel™ (Rufinamide).....II-146
Progenics Receives FDA Approval for RELISTOR .....II-146
J&J Receives Approval for Anti-HIV Medication ‘Intelence’ .....II-146
Sandoz Launches Generic Fluoxetine Hydrochloride Capsules in US.....II-146
1$100
   Sandoz Introduces Eplerenone Tablets.....II-147
Wockhardt Introduces Midazolam Injection in the US.....II-147
Dr. Reddy’s Announces Launch of Generic Version of Imitrex® Tablets.....II-147
Arbor Pharmaceuticals Debuts NEOTIC™ for Middle- Ear Infections.....II-147
Promius Pharma Introduces EpiCeram® Emulsion.....II-147
1$100
   Sandoz Unveils Generic Variant of Imitrex® Injection.....II-148
Dr. Reddy’s Launches Redihaler™ and Combihale™.....II-148
Wyeth Launches Antihemophilic Factor, XYNTHA™.....II-148
Bayer Schering Releases YAZ®.....II-148
1$100
   Mylan Introduces Nisoldipine ER Tablets in US.....II-149
Ranbaxy Launches Generic Omeprazole in US.....II-149
Ranbaxy Unveils Generic Equivalent of Amlodipine Tablets.....II-149
Teva Unveils Generic Equivalent of Lamictal® Tablets.....II-149
1$100
   Eisai and Helsinn Healthcare Introduce ALOXI® Injection for Prevention of
  PONV.....II-150
Janssen and Patriot Unveil Authorized Generic Equivalent for Risperdal®.....II-150
Watson Releases Generic Equivalent of MARINOL®.....II-150
1$100
   Sandoz Introduces Generic Form of Altace®.....II-151
Abbott Introduces Aluvia® Tablet in South Africa.....II-151
Dr. Reddy’s Rolls-out Atocor-R.....II-151
Sandoz Unveils Generic Form of Maxipime®.....II-151
1$100
   Tibotec Therapeutics Introduces New 600mg Dosage Strength for PREZISTA.....II-152
Ranbaxy Pioneers Launch of New Bio-Generic Recombinant Osteoporosis
  Injection.....II-152
Sandoz Introduces Generic Variant of Antizol® Injection.....II-152
Sun Pharmaceuticals Introduces Injection of Amifostine.....II-152
1$100
   Sandoz Re-Launches Generic Form of Bactocill® Injection.....II-153
Sandoz Introduces Generic Form of Cipro® Injection.....II-153
Merck Serono Introduces Cyanokit® in Japanese Market.....II-153
Ranbaxy Launches INERSAN Tablets in India and Nepal.....II-153
Sandoz Launches Omnitrope™ Pen 5 with Liquid Cartridge.....II-153
1$100
   Endo Pharmaceuticals to Introduce OPANA® ER in Three Dosage Strengths.....II-154
Sandoz Releases Generic Form of Camptosar®.....II-154
Sun Pharmaceuticals Unveils Pantoprazole Sodium DR Tablets.....II-154
Dr. Reddy’s Introduces Supanac®.....II-154
1$100
   Watson Announces Launch of Clarithromycin 500mg Extended-Release Tablets.....II-155
GSK Announces FDA approval of Altabax™ .....II-155
Novartis’ Tekturna HCT® Receives FDA Approval .....II-155
GSK Receives FDA Approval for Tykerb® .....II-155
Pfizer Receives FDA Approval for Selzentr .....II-155
Ortho-McNeil Receives Approval for DORIBAX™ .....II-155
1$100
   Merck Receives Approval for Isentress® .....II-156
BMS Wins FDA Approval for IXEMPRA™ .....II-156
Novartis’ Tasigna® Receives FDA Approval .....II-156
Mylan Receives FDA Approval for Bystolic .....II-156
Roche’s Mircera Secures FDA Approval .....II-156
1$100
   Eisai Launches New Dose Formulations of Aricept® Tablets in Japan.....II-157
Chugai Launches Tarceva® Tablet in Japan.....II-157
Sandoz Introduces Generic Version of Elocon® Lotion.....II-157
Ranbaxy to Introduce Tamsulosin Hydrochloride Capsules in Canada.....II-157
Watson Unveils Tilia™ Fe.....II-157
1$100
   Ranbaxy Obtains Health Canada Approval for Ran®- Lisinopril Oral Tablets.....II-158
Sandoz Releases Generic Form of Delestrogen® Injections.....II-158
Sanofi and UCB Roll Out XYZAL® in US.....II-158
1$100
   Sandoz Expands Range of Generic Augmentin® Drugs.....II-159
Sandoz Releases Generic Variant of Biaxin® for Oral Suspension.....II-159
Sandoz Introduces Generic Form of Penlac® Topical Solution.....II-159
Teva Releases Famciclovir Tablets.....II-159
Ranbaxy Introduces Roliflo OD in India.....II-159
1$100
   Sandoz Introduces Generic Form of Toprol Xl® 50Mg Extended Release Tablet.....II-160
Dr. Reddy’s Introduces Glimy MP1 and Glimy MP2.....II-160
Sandoz Launches Approved Generic Equivalent of Lamisil®.....II-160
Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US.....II-160
AstraZeneca Announces the Availability of Symbicort® pMDI.....II-160
1$100
   Chugai and Maruho Announce the Launch of Oxarol® Lotion.....II-161
Ajinomoto and Eisai Jointly Launch ‘Actonel® 17.5mg Tablets’.....II-161
Sandoz Introduces Approved Generic Form of Lotrel®.....II-161
1$100
   Dr. Reddy’s Launches UltravexTM.....II-162
Wockhardt Unveils Zolpidem Tablets in the US.....II-162
Dr. Reddy’s Introduces Reditux™.....II-162
Dr. Reddy’s Secures Approval for Launching Zolpidem Tartrate Tablets.....II-162
Cipla Introduces Virenza Inhalation Capsules in India.....II-162
1$100
   Ranbaxy Introduces Osovair in India.....II-163
GlaxoSmithKline Introduces Coreg CR™.....II-163
Chugai Announces the Launch of Antiviral Agent, Copegus® Tablet.....II-163
Ranbaxy Unveils Generic Atorvastatin in Denmark.....II-163
1$100
   Barr Unveils Generic ‘PROSCAR®’ Tablets.....II-164
Ranbaxy Introduces Niftran 100mg Capsules and Eligard 22.5mg and 45mg.....II-164
Barr Releases METAGLIP™ Tablets.....II-164
1$100
   SkinMedica Rolls Out Single-Dosage NeoBenz® Micro SD for Treating Acne.....II-165
Teva Rolls Out Generic Equivalent of Wellbutrin XI® Tablets.....II-165
Takeda Launches Takepron ® I.V for Injection 30mg.....II-165
1$100
   Takeda Launches duetact™ Combination Drug in USA.....II-166
Teijin Pharma Launches Bonalon® Tablet for Treating Osteoporosis.....II-166
1$100
   Abbott Laboratories (USA).....II-167
Allergan, Inc. (USA).....II-167
1$100
   Amgen, Inc. (USA).....II-1681$100
   AstraZeneca (UK).....II-1691$100
   Bayer AG (Germany).....II-170
Bristol-Myers Squibb (USA).....II-170
Boehringer Ingelheim Group (Germany).....II-170
1$100
   Dr. Reddy's Laboratories Ltd. (India).....II-1711$100
   Eli Lilly and Company (USA).....II-172
F. Hoffmann-La Roche Ltd. (Switzerland).....II-172
1$100
   Genentech, Inc. (USA).....II-173
GlaxoSmithKline Plc (UK).....II-173
1$100
   Johnson & Johnson, Inc. (USA).....II-174
Merck & Co. Inc. (USA).....II-174
1$100
   Merck Serono International S.A. (Switzerland).....II-175
Mylan, Inc. (USA).....II-175
1$100
   Novartis AG (Switzerland).....II-1761$100
   Pfizer, Inc. (USA).....II-177
Ranbaxy Laboratories Limited (India).....II-177
1$100
   Sanofi-Aventis SA (France).....II-178
Sanofi Pasteur (France).....II-178
1$100
   Takeda Pharmaceutical Company Limited (Japan).....II-179
Teva Pharmaceutical Industries Ltd. (Israel).....II-179
1$100
   Watson Pharmaceuticals, Inc. (USA).....II-1801$100
   Wyeth (USA).....II-181
1$100
   Table 25: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1821$300
   Table 26: World Historic Review for Prescription Drugs Market by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-1831$300
   Table 27: World 15-year Perspective for Prescription Drugs Market by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-1841$300
   Table 28: World Recent Past, Current & Future Analysis for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1851$300
   Table 29: World Historic Review for Prescription Drugs Market by Therapeutic Class – Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets Independently Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....II-1861$300
   Table 30: World 15-year Perspective for Prescription Pharmaceuticals Market by Therapeutic Class– Percentage Breakdown of Dollar Sales for Oncologics, Lipid Regulators, Respiratory Agents, Proton Pump Inhibitors, Antidiabetics, Antipsychotics, Antidepressants, Angiotensin II Antagonists, Anti-Epileptics, Autoimmune Agents and Others Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-1871$300
   A. Market Analysis.....III-1
Generics in the US.....III-1
Biologics Post Highest Growth.....III-1
1$75
   Leading Prescription Drugs in the US.....III-2
Table 31: Leading Prescription Drugs in the US by Value Sales (2008) in US$ Billion - Lipitor, Nexium, Plavix, Advair Diskus, Seroquel, Singulair, Enbrel, Neulasta, Actos and Epogen (includes corresponding Graph/Chart).....III-2
Leading Therapeutic Classes in the US.....III-2
1$150
   Table 32: US Leading Therapeutic Classes by Revenue (2006-2008): Revenues for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorders, Anti-Depressants, Angiotensin II Antagonists, Anteneo Monoclonal Antibodies, Erythropoietins, Anti-Arthritics and Oral Antiplatelets (in US$ Billion) (includes corresponding Graph/Chart).....III-31$150
   Table 33: US Leading Therapeutic Classes by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Lipid Regulators, Codiene & Combinations, Anti-Depressants, Ace Inhibitors, Beta Blockers, Proton Pump Inhibitors, Seizure Disorders, Synthetic Thyroid Hormones, Calcium Blockers, Benzodiazepines, and Others (includes corresponding Graph/Chart).....III-41$150
   Leading Players.....III-5
Table 34: Leading Companies in the US Pharmaceutical Market (2006-2008): Percentage Breakdown of Value Sales for Pfizer, GlaxoSmithKline, Merck & Co., Johnson & Johnson, AstraZeneca, Amgen, Novartis, Hoffman-La Roche, Sanofi-Aventis, Eli Lilly and Others (includes corresponding Graph/Chart).....III-5
1$150
   Table 35: US Pharmaceutical Market (2006-2008): Percentage Breakdown of Dispensed Prescriptions for Teva Pharmaceuticals, Mylan Laboratories, Novartis, Watson Pharma, Pfizer, Barr Laboratories, Merck & Co., Mallinckrodt, Apotex, Qualitest, and Others (includes corresponding Graph/Chart).....III-6
Prescription Drug Spending.....III-6
1$150
   Table 36: Healthcare Spending in the US by Sector (2006) (includes corresponding Graph/Chart).....III-71$150
   Increasing Share of Government in Prescription Drug Spending.....III-8
Table 37: US Prescription Pharmaceutical Industry (2005 and 2006): Percentage Breakdown of Prescription Pharmaceutical Spending by Source for Private Insurance, Medicare, Medicaid, Out-of-Pocket and Other Public Spending (includes corresponding Graph/Chart).....III-8
Medicare Part D.....III-8
1$150
   Drug Price Regulations in the US.....III-9
Pharmaceutical Marketing – A High Investment Area in the US.....III-9
1$75
   Table 38: Pharmaceutical Promotional Spending in the US by Type (2006-2008): Professionals-Directed Promotions and Consumer-Directed Promotions (in US$ Billion) (includes corresponding Graph/Chart).....III-10
Major Distribution Channels.....III-10
1$150
   Table 39: Major Prescription Drugs’ Distribution Channels in the US by Dispensed Prescriptions (2006-2008): Percentage Share Breakdown for Chain Stores, Independent Stores, Food Stores, Long-term Care, and Mail Order (includes corresponding Graph/Chart).....III-11

Table 40: Major Prescription Drugs’ Distribution Channels in the US by Value Sakes (2006-2008): Percentage Breakdown for Distribution Channel for Chain Stores, Mail Order, Independent Stores, Clinics, Non-government Hospitals, Food Stores and Other Channels (includes corresponding Graph/Chart).....III-11
1$150
   Fewer Product Launches.....III-12
Generic Penetration and PBMs Moderate Prescription Drug Price Growth.....III-12
Co-payment Differentials to Increase Generic Substitution.....III-12
High Prescription Drug Costs Drive Drug Re- Importation.....III-12
Direct-to-Consumer Advertising.....III-12
1$75
   The 2006 Revision of Package Insert Format.....III-13
Other Initiatives.....III-13
Role of PBMs in the Pharmaceutical Supply Chain.....III-13
1$75
   Prescription Drug Pricing in US.....III-141$75
   Role of Mail-Order Pharmacies in Cost Containment.....III-15
Product Launches.....III-15
15$725
   Strategic Corporate Developments.....III-3033$975
   Select Key Players.....III-638$400
   B. Market Analytics.....III-71
Table 41: US Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-71

Table 42: US Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-71
1$150
   Table 43: US Recent Past, Current & Future Analysis for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-721$150
   Table 44: US Historic Review for Prescription Pharmaceuticals by Therapeutic Class – Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, Others, Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-731$150
   Table 45: US 15-Year Perspective for Prescription Pharmaceuticals by Therapeutic Class – Percentage Breakdown of Dollar Sales for Antipsychotics, Lipid Regulators, Proton Pump Inhibitors, Seizure Disorder Drugs, Anti-Depressants, Angiotensin II Antagonists, Antineo Monoclonal Antibodies, Erythropoietins, and Others for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....III-74
1$150
   A. Market Analysis.....III-75
Current and Future Analysis.....III-75
Leading Drugs.....III-75
Table 46: Leading Prescription Drugs in Canada in Terms of Number of Dispensed Prescriptions (2006 and 2007) in Million Scripts: Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio-Salbutamol Hfa, Novo-Venlafaxine XR and Apo- Furosemide (includes corresponding Graph/Chart).....III-75
1$150
   Major Therapeutic Classes.....III-76
Table 47: Leading Therapeutic Classes in Canada in terms of Dispensed Prescription (2006 and 2007): Percentage Breakdown of Cardiovascular, Antipsychotics, Gastrointestinal/Genitourinary, Lipid Regulators, Hormones, Systemic Anti-infective, Analgesics, Diabetes Therapy, Diuretics, Neurological Disorders and Others (includes corresponding Graph/Chart).....III-76
1$150
   Prescription Drugs Spending on the Rise.....III-77
Private Sector Insurance Continues to Gain Popularity.....III-77
Canadian Prescription Drugs Market- A Comparison with the US.....III-77
Generic Sales to Outpace Branded Drugs Sales.....III-77
Generics Market in Canada.....III-77
Generics to Offer Potential Cost Savings.....III-77
1$75
   New Patented Drugs- Adding Costs but Little Value.....III-78
Two-level Drug Approval Process in Canada.....III-78
Policy Differences Affect Generic Substitution Among Provinces.....III-78
Applied and Other Research Take Major Chunk of R&D Investments in Canada.....III-78
1$75
   Table 48: Investments in Research & Development in Canada (1998, 2001, 2004 and 2007): Percentage Breakdown by Research Type- Applied Research, Basic Research and Other Research Areas (includes corresponding Graph/Chart).....III-79
Product Launches.....III-79
2$300
   Strategic Corporate Developments.....III-811$75
   B. Market Analytics.....III-82
Table 49: Canadian Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-82

Table 50: Canadian Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-82
1$150
   A. Market Analysis.....III-83
Current and Future Analysis.....III-83
Generics Promotion in Japan.....III-83
Ageing Population – A Prime Target.....III-83
1$75
   Competitive Landscape.....III-84
Table 51: Leading Pharmaceutical Companies in Japan (2008): Percentage Breakdown of Revenues for Takeda Pharmaceuticals, Astellas Seiyaku, Dai-ichi Sankyo, Mitsubishi Tanabe, Chugai Seiyaku, Pfizer, Novartis, Eisai, GlaxoSmithKline and Otsuka Seiyaku (includes corresponding Graph/Chart).....III-84
1$150
   Table 52: Leading Prescription Drugs in Japan (2008): Value Sales in US$ Million for Blopress, Diovan, Norvasc, Lipitor, Aricept, Epogin, Takepron, Leuplin, Micardis and Amlodin (includes corresponding Graph/Chart).....III-85
Cancer Drugs to Witness Robust Growth.....III-85
Biennial Price Reduction to Impact Markets of Key Therapeutic Classes.....III-85
1$150
   Product Launches.....III-862$150
   Strategic Corporate Developments.....III-886$250
   Select Key Players.....III-941$75
   B. Market Analytics.....III-95
Table 53: Japanese Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-95

Table 54: Japanese Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-95
1$150
   A. Market Analysis.....III-96
Current and Future Analysis.....III-96
Pharmaceutical Spending on the Rise.....III-96
Mounting Healthcare Bills Boost Generic Drugs Consumption.....III-96
1$75
   Biogenerics Foray into Europe.....III-97
SNRIs Likely to Replace SSRIs.....III-97
Research and Development.....III-97
Table 55: European Investments in Pharma Research & Development: 2005-2007 (includes corresponding Graph/Chart).....III-97
1$150
   Europe - The Research and Production Hub for Vaccines Worldwide.....III-98
Parallel Trade in Europe.....III-98
New Rules to Offer Respite to Parallel Traders.....III-98
Manufacturers Seek Greater Control Over Supply Chain.....III-98
1$75
   Pharmaceutical Industry Overview In Select Countries.....III-99
France.....III-99
Germany.....III-99
Generics.....III-99
1$75
   Exports.....III-100
Production.....III-100
Prices.....III-100
New Molecular Entities.....III-100
R&D Investments.....III-100
Parallel trade.....III-100
1$75
   Genetically Manufactured Drugs.....III-101
Table 56: German Genetically Manufactured Pharmaceuticals (2007): Percentage Breakdown of Sales by Type - Vaccines, Insulins, Interferons, Monoclonal Antibodies, Erythropoietin, and Others (includes corresponding Graph/Chart).....III-101
United Kingdom.....III-101
Spain.....III-101
1$150
   Cost Containment Efforts.....III-102
Increased Promotion for Generics.....III-102
Re-launch of Reference Price System.....III-102
Distribution.....III-102
1$75
   Italy.....III-103
Generics Gain Traction.....III-103
Sweden.....III-103
Greece.....III-103
Unique Pricing Model for Drugs.....III-103
1$75
   Product Launches.....III-1042$150
   Strategic Corporate Developments.....III-10617$800
   Select Key Players.....III-1235$375
   B. Market Analytics.....III-128
Table 57: European Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-128
1$150
   Table 58: European Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-129
1$150
   A. Market Analysis.....III-130
Current and Future Analysis.....III-130
Overview of Pharmaceutical Industries in Select Countries.....III-130
India.....III-130
Competitive Advantage.....III-130
1$75
   Number of FDA Approved Plants in India Vis-à-Vis Other Countries.....III-131
Increasing Disposable Income Driving Consumption of Drugs.....III-131
Generics to Surge Growth in Exports.....III-131
Manufacturers Continue to Target Developed Markets.....III-131
1$75
   India to Emerge as an Important Pharmaceutical Manufacturing Center.....III-132
Threat from Other Asian Countries.....III-132
India to Emerge as a Major Hub for Biogenerics.....III-132
Acute Therapy Class Leads the Market.....III-132
1$75
   Table 59: Leading Therapeutic Categories in the Indian Pharmaceutical Industry- Percentage Share Breakdown of Value Sales for Anti-infectives, Gastrointestinal, Cardiovascular, Respiratory, Minerals and Vitamins, Analgesics, Women’s Health, Central Nervous System, Dermatology, and Others (includes corresponding Graph/Chart).....III-133
Increase in Private Healthcare Services.....III-133
China.....III-133
1$150
   Chinese Pharma Industry Remains Immune to Global Crisis, for Now.....III-134
Issues and Trends.....III-134
1$75
   Pharmaceutical Firms to Play Pivotal Role in Transforming Healthcare
  System.....III-135
Brand Name Drugs to Exhibit Fastest Growth, While Generics Continue to
  Lead.....III-135
Generics in China.....III-135
1$75
   Traditional Medicines – Substantial Share.....III-136
Table 60: Leading Medicine Types in China (2005): Percentage share for Allopathic Medicines, Traditional Chinese Medicines (TCM), and Other Drugs (includes corresponding Graph/Chart).....III-136
1$150
   Underserved Markets Prompt Government to Foster Development.....III-137
Domestic EPO Market Booming, Domestic Players Continue their Domination.....III-137
Chinese Antipsychotics Market to Witness Substantial Growth.....III-137
1$75
   Antidepressant Drugs to Exhibit Robust Sales.....III-138
Indonesia.....III-138
Market Features.....III-138
Government-Enforced Pricing Control Over Essential Drugs.....III-138
1$75
   Distribution.....III-139
Korea.....III-139
Patent Expiries of Leading Drugs in South Korea: 2008 and 2009.....III-139
1$75
   Malaysia.....III-140
Foreign Investments on the Rise.....III-140
Domestic Market.....III-140
1$75
   Australia.....III-141
Pharmaceutical Benefits Scheme.....III-141
1$75
   Government’s Industry Development Programs.....III-142
Outlook.....III-142
1$75
   Product Launches.....III-1433$225
   Strategic Corporate Developments.....III-1467$375
   Select Key Players.....III-1532$150
   B. Market Analytics.....III-155
Table 61: Asia-Pacific Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-155

Table 62: Asia-Pacific Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-155
1$150
   A. Market Analysis.....III-156
Current and Future Analysis.....III-156
Strategic Corporate Developments.....III-156
1$75
   B. Market Analytics.....III-157
Table 63: Latin American Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-157

Table 64: Latin American Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-157
1$150
   A. Market Analysis.....III-158
Current and Future Analysis.....III-158
Product Launches.....III-158
Strategic Corporate Developments.....III-158
2$150
   B. Market Analytics.....III-160
Table 65: Rest of World Recent Past, Current & Future Analysis for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-160

Table 66: Rest of World Historic Review for Prescription Drugs Market Analyzed with Annual Sales in US$ Billion for Years 2001 through 2005 (includes corresponding Graph/Chart).....III-160
1$150
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com